CIK 0000921299
- Non-accelerated filer
- Smaller reporting company
KYNTRA BIO, INC.
Sign in to watch- Ticker
- KYNB
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 770357827
- Phone
- +1 415-978-1200
- Business address
- 350 BAY STREET, SUITE 100 #6009, SAN FRANCISCO, CA, 94133
- Former names
- FIBROGEN INC
- 4 Shares withheld for taxes SVP, Finance and CFO gave up 3,014 shares (to pay taxes)
- 4 Shares withheld for taxes SVP, China Operations gave up 3,039 shares (to pay taxes)
- 4 Grant or award Incoming Chief Medical Officer acquired 35,000 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Exercise or conversion SVP, Clinical Dev, Drug Safety acquired 7,082 shares (option exercise)
- 4 Open-market sale Chief Medical Officer sold 3,351 shares at $44.01 ($147,478)
- 4 Open-market sale SVP, Finance and CFO sold 3,070 shares at $43.63 ($133,944)
- 4 Shares withheld for taxes Chief Medical Officer gave up 3,291 shares (to pay taxes)
- 4 Shares withheld for taxes SVP, Clinical Dev, Drug Safety gave up 2,728 shares (to pay taxes)
- 4 Shares withheld for taxes SVP, Finance and CFO gave up 3,014 shares (to pay taxes)
- 4 Shares withheld for taxes SVP, China Operations gave up 3,038 shares (to pay taxes)
- 4 Open-market sale Chief Medical Officer sold 10,000 shares at $50.89 ($508,900)
- 4 Open-market sale SVP, Finance and CFO sold 15,004 shares at $50.91 ($763,854)
- 4 Exercise or conversion Director acquired 6,000 shares (option exercise)
- 4 Open-market sale SVP, Finance and CFO sold 22,554 shares at $48.00 ($1,082,592)
- 4 Grant or award Director acquired 3,914 shares (grant or award)
- 4 Grant or award Director acquired 3,914 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale Chief Medical Officer sold 3,351 shares at $42.35 ($141,915)
Page 12 of 38 · 760 filings